The palatability and tolerability of deferasirox taken with different beverages or foods

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages 1507-1512

  Goldberg, Stuart L ^a   Giardina, Patricia J ^b   Chirnomas, Deborah ^c   Esposito, Jason ^d   Paley, Carole ^d   Vichinsky, Elliott ^e  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Administration; Anemia; Deferasirox; Food; Palatability; Tolerability

Indexed keywords

CREATININE; DEFERASIROX; FERRITIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BEVERAGE; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HEMOSIDEROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; PALATABILITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; THALASSEMIA MAJOR; UPPER ABDOMINAL PAIN; VOMITING;

ADMINISTRATION; ANEMIA; DEFERASIROX; FOOD; PALATABILITY; TOLERABILITY;

ADOLESCENT; BENZOATES; BEVERAGES; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FOOD; FOOD-DRUG INTERACTIONS; HEMATOLOGIC DISEASES; HEMOSIDEROSIS; HUMANS; IRON CHELATING AGENTS; MALE; TRIAZOLES;

EID: 84880331995     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24561     Document Type: Article

References (11)

1. De Luca C, Filosa A, Grandinetti M, et al. Blood antioxidant status and urinary levels of catecholamine metabolites in β-thalassemia. Free Radic Res 1999; 30:453-462.
2. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567-573.
3. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Thalassemia clinical research network complications of β-thalassemia major in North America. Blood 2004; 104:34-39.
4. Exjade [package insert], East Hanover, NJ: Novartis Pharmaceutical Corporation; 2010.
5. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361:1597-1602.
6. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol 2009; 82:454-457.
7. Séchaud R, Dutreix C, Balez S, et al. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther 2008; 46:102-108.
8. Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: Recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol 2008; 48:428-435.
9. European Medicines Agency. EPAR [European public assessment report] summary for the public: Ferriprox. http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000236/human_med_000789.jsp. Published June 2010. Accessed December 6, 2012.
10. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455-3462.
11. McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: A systematic review and economic evaluation. Health Technol Assess 2009; 13:iii-iv, ix-xi, 1-121.